Isomorphic Labs announced a $2.1 billion Series B funding round led by Thrive Capital, one of the largest biotech venture raises in recent years. The company’s stated goal is to scale its predictive AI models for drug discovery and apply them more broadly across drug development workflows. The financing adds to a growing set of AI-centric capital commitments in drug discovery, and it follows other record rounds in the sector focused on model-driven optimization rather than solely data collection. Isomorphic said it will use the expanded resources to deploy its models at greater scale, including with a product introduced earlier in the year. For biotech investors and BD leaders, the size of the round underscores continued willingness to fund foundation-model-like approaches that promise to compress hit-to-lead and lead optimization cycles—assuming outputs translate into experimentally validated targets and molecules.